Doravirine

	Interaction Color Code	Clinical Bottom Line	Clinical Effects	Drug 1 effect	Drug 2 dose	Drug 2 effect	Management
Doravirine EFV 359	Red: Avoid combination	Do not coadminister: Reduced levels of doravirine	Potential decrease in antiretroviral efficacy	AUC decreased 62%; Cmax decreased 35%; C24 decreased 85%	600 mg x 1	Not studied	Do not coadminister. Use alternative agents.
Doravirine EFV 358	Red: Avoid combination	Do not coadminister: Reduced levels of doravirine	Potential decrease in antiretroviral efficacy	AUC decreased 32%; Cmax decreased 14%; C24 decreased 50%	600 mg daily x 14 days	Not studied	Do not coadminister. Use alternative agents.
Doravirine RIF 357	Red: Avoid combination	Do not coadminister: Reduced levels of doravirine	Potential decrease in antiretroviral efficacy.	AUC decreased 88%; Cmax decreased 57%, Cmin decreased 97%	600 mg daily	Not studied	Contraindicated. Use alternative agents. If discontinuing the rifamycin, at least a 4 week cessation period is recommended prior to beginning doravirine.
Doravirine RFB 356	Red: Avoid combination	Do not coadminister: Reduced levels of doravirine	Potential decrease in antiretroviral efficacy	AUC decreased 50%; Cmin decreased 68%	300 mg daily	Not studied	Contraindicated. Use alternative agents. If discontinuing the rifamycin, at least a 4 week cessation period is recommended prior to beginning doravirine.
Doravirine NVP 355	Red: Avoid combination	Do not coadminister: Potential for reduced levels of doravirine	Potential decrease in antiretroviral efficacy				Do not coadminister. Use alternative agents.
Doravirine ETR 354	Red: Avoid combination	Do not coadminister: Potential for reduced levels of doravirine	Potential decrease in antiretroviral efficacy				Do not coadminister. Use alternative agents.
Doravirine St. John's Wort (Hypericum perforatum) 353	Red: Avoid combination	Do not coadminister: Potential for reduced levels of doravirine	Potential decrease in antiretroviral efficacy				Contraindicated. Use alternative agents. If discontinuing St. John's Wort, a minimum 4 week cessation period is recommended prior to initiating doravirine.
Doravirine Phenytoin 352	Red: Avoid combination	Do not coadminister: Potential for reduced levels of doravirine	Potential decrease in antiretroviral efficacy				Contraindicated. Use alternative agents. If discontinuing phenytoin, a minimum 4 week cessation period is recommended prior to initiating doravirine.
Doravirine Phenobarbital 351	Red: Avoid combination	Do not coadminister: Potential for reduced levels of doravirine	Potential decrease in antiretroviral efficacy				Contraindicated. Use alternative agents. If discontinuing phenobarbital, a minimum 4 week cessation period is recommended prior to initiating doravirine.
Doravirine Oxcarbazepine 350	Red: Avoid combination	Do not coadminister: Potential for reduced levels of doravirine	Potential decrease in antiretroviral efficacy				Contraindicated. Use alternative agents. If discontinuing oxcarbazepine, a minimum 4 week cessation period is recommended prior to initiating doravirine.
Doravirine Mitotane 349	Red: Avoid combination	Do not coadminister: Potential for reduced levels of doravirine	Potential decrease in antiretroviral efficacy				Contraindicated. Use alternative agents. If discontinuing mitotane, a minimum 4 week cessation period is recommended prior to initiating doravirine.
Doravirine Enzalutamide 348	Red: Avoid combination	Do not coadminister: Potential for reduced levels of doravirine	Potential decrease in antiretroviral efficacy				Contraindicated. Use alternative agents. If discontinuing enzalutamide, a minimum 4 week cessation period is recommended prior to initiating doravirine.
Doravirine Carbamazepine 347	Red: Avoid combination	Do not coadminister: Potential for reduced levels of doravirine	Potential decrease in antiretroviral efficacy				Contraindicated. Use alternative agents. If discontinuing carbamazepine, a minimum 4 week cessation period is recommended prior to initiating doravirine.
Doravirine Ketoconazole 346	Green: Administer standard doses	Administer standard doses	Potential for increased doravirine adverse effects	AUC increased to 306%; Cmax increased by 25%; C24 increased to 275%	400 mg daily	Not studied	No dose adjustment necessary. Monitor for doravirine adverse effects.
Doravirine RTV 345	Green: Administer standard doses	Administer standard doses	Potential for increased doravirine adverse effects	AUC increased to 354%; Cmax increased by 31%; C24 increased to 291%	100 mg BID	Not studied	No dose adjustment necessary. Monitor for doravirine adverse effects.
Doravirine Omeprazole 344	Green: Administer standard doses	Administer standard doses	Potential decrease in antiretroviral efficacy.	AUC decreased 17%; Cmin decreased 16%
Doravirine

Subscribe to Doravirine